Portfolio Company:


SkinJect is developing a novel treatment for common forms of non-melanoma skin cancer.

The device comprises a dissolvable microneedle array (MNA) to deliver a drug directly into the top layer of skin, which will kill non-melanoma skin cancer by causing an immune system reaction to combat the disease. SkinJect is a development stage company actively working to advance the technologies and related patent portfolio to commercial standards.

Portfolio news